cyrilzakka/clinical-trials huggingface dataset:
Virtual Reality's Impact on Upper Limb Function in Post-stroke Patients

Stroke rank second among the top causes of death, affecting millions of people in the worldwide. Approximately 70-80% survivors of stroke could experience various levels of upper limb motor impairments, which seriously affects the activities of daily life and cause serious physical and mental burden to patients and their families. As bottleneck effect in traditional rehabilitation techniques become apparent, a number of emerging technologies are being used in rehabilitation treatment in an attempt to break down this barrier.Studies have shown that virtual reality (VR) training can effectively promote the remodeling of the central nervous system and has become an important research direction for motor function rehabilitation.However, most current studies still focus on evaluating the overall intervention effect of VR, with little examination of its intrinsic properties and a lack of exploration of the sense of ownership (SOO) and agency (SOA).

Hence, this study conducted different VR interventions on stroke patients to evaluate the effects of the intrinsic properties of VR and the body illusion it produces on the rehabilitation of their upper limb motor function.

This study is a single-blind randomized controlled trial. A total of 120 participants will be enrolled and divided into a control group, an interactive VR group, and an immersive and interactive VR group. All groups will be tested on the virtual hand illusion before the intervention. The intervention will last for a fortnight, four times a week for one hour each time. Assessment will be conducted before the intervention, at the end of the intervention, and at week 6 for follow-up. The primary outcome measure is the "Fugl-Meyer Assessment of the Upper Extremity (FMA-UE)". The secondary outcome measures are "SOO questionnaire", "proprioceptive drift scale", "action research arm test (ARAT)", "NIH stroke scale (NIHSS)", "mini mental state examination (MMSE)", "electromyography (EMG)", "electroencephalography (EEG)" and "functional Magnetic Resonance Imaging (fMRI)".


Eligibility Criteria:
Inclusion Criteria:

* First episode of stroke, hemorrhagic or ischemic, confirmed by computed tomography or magnetic resonance imaging of the brain;
* Age 40-80 years, either male or female;
* 3-12 months since stroke occurrence;
* Mild-to-moderate or moderate-to-severe upper extremity impairment, with a FMA-UE score between 16 and 53;
* Basic ability to communicate and comprehend the research instructions, with a score of 21 and above on the MMSE scale;
* Agreement to participate in the study, with an informed consent form duly signed by the patient or a family member.

Exclusion Criteria:

* The presence of ferromagnetic metals implanted in the body;
* Visual or hearing deficits;
* Unstable medical conditions;
* History of receiving similar VR training in the past;
* A history of myasthenia gravis, multiple sclerosis, muscular dystrophy, or other diseases that may cause upper limb movement disorders.
Interventions Made to Preserve Cognitive Function

This is a randomized, controlled trial to slow cognitive decline in adults undergoing hemodialysis (HD). The investigators will test three interventions cognitive training (CT), exercise training (ET), and combined cognitive and exercise training (CT+ET) relative to standard of care (SC).

This will be a two by two factorial, randomized, controlled trial to slow cognitive decline in adults undergoing hemodialysis (HD). The investigators primary objective is to determine if receiving cognitive training (tablet-based brain games), exercise training (stationary foot pedal), or combined cognitive and exercise training preserves executive function relative to those with standard of care . The secondary objectives are to compare the rates of end stage renal disease (ESRD)-specific clinical outcomes and patient centered outcomes among those receiving CT, or ET, or CT+ET relative to those in SC. The investigators will formally test whether receiving CT or ET will preserve executive function and receiving combined CT+ET will preserve executive function better than CT or ET alone.

Eligibility Criteria:
Inclusion Criteria:

* 18 years or older at enrollment
* English speaking
* within 3 months to 3 years of initiating hemodialysis
* receiving hemodialysis at participating dialysis centers

Exclusion Criteria: Patients with the following conditions will be excluded:

* Pregnancy
* Angina Pectoris
* Chronic lung disease requiring oxygen
* Musculoskeletal conditions that limit mobility
* Upper or lower extremity amputation
* Orthopedic disorders exacerbated by physical activity
* Femoral arteriovenous (AV) access
* Hepatitis B infection
* Blindness/Legal blindness

In addition to conditions outlined above, patients who are currently incarcerated will be excluded from the study.
Electromyography to Diagnose Neuromuscular Disorders

This study will investigate problems with muscle weakness and control using electromyography-a test of nerve-muscle cell communication. Advanced techniques called single fiber electromyography and macro-electromyography, which evaluate individual muscle fibers, will be used. Besides aiding in diagnosis, these tests provide information about disease progression that may be useful in guiding therapy.

Adult patients with suspected neurological disorders of muscle control and weakness may be eligible for this study. Normal volunteers may also participate. For the electromyography procedure, a special needle is inserted into a muscle. The patient will slightly tense the muscle and maintain the tension while electrical signals from the muscle fibers are being recorded. The electrical signals are played through a loudspeaker, providing feedback to help the patient tense the muscle the appropriate amount. The test, which is usually done for only one muscle, takes 1 to 2 hours. If needed, short breaks can be taken.

If the patient cannot maintain tension in the muscle for the entire test period, a nerve will be stimulated to activate the muscle. A thin needle is inserted near the nerve, and a series of small electrical shocks are given to activate a nerve fiber. The electromyography needle is inserted into the muscle to measure the response, as described above.

A neurologist receiving specialized training in clinical neurophysiology will do the electromyography procedure under the direct supervision of an experienced neurologist.

This is a training protocol to enable fellows in clinical neurophysiology to learn and perform technically advanced electrodiagnostic studies, such as single fiber EMG and macro EMG, on patients with neuromuscular diseases.

Eligibility Criteria:
INCLUSION CRITERIA:

Adult patients with weakness or motor dysfunction: 8/year.

Normal volunteers, adults: 2/year.

EXCLUSION CRITERIA:

Anticoagulation or uncorrected bleeding disorder.

Children are not optimal subjects for fellows undergoing training in these techniques and will be excluded.
Maternal Non-Stress Testing

Percent agreement of vital signs monitoring between the experimental sensor and standard of care monitoring


Eligibility Criteria:
Inclusion Criteria:

* Maternal age \>18 years old
* Pregnant mothers \>26 weeks undergoing nonstress testing or delivering
* Singleton pregnancy
* No fetal abnormality or chromosomal abnormality
* Subjects willing and able to comply with requirements of the protocol
* Nurses and clinicians who will be administering the non-stress test to the pregnant subject

Exclusion Criteria:

* Women who refuse to signed the informed consent form
* Maternal age under 18 years old
* Multiple pregnancy
* Known major fetal malformation or chromosomal abnormality
* Medical or obstetric problem that would preclude the use of abdominal electrodes
* Inability to consent to this study due to medical illness, diminished intellectual capacity, or language barrier
* Women using pacemakers
Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest

During thoracic aortic surgery, hypothermic cardiac arrest causes aortic ischemia and reperfusion (IR) periods, respectively. Aortic ischemia results in an ischemic insult to the lower extremities and successive reperfusion results in injury to remote organs, including kidneys. So, there has been considerable interest in the development of therapeutic strategies aimed at attenuating IR injury. One such group of agents that are attracting interest due to their potential protective effects on vascular endothelium is the erythropoietin.

However, the effect of erythropoietin on renal injury induced by aortic IR in humane has not been fully clarified. Therefore, the purpose of this study is to determine whether the prophylactic administration of erythropoietin reduce the incidence of acute kidney injury (AKI) in patients undergoing thoracic aorta surgery with hypothermic cardiac arrest. The investigators administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia. The differences between the control and study groups are observed by clinical indicators such as serum creatinine, TNF-α, NGAL.


Eligibility Criteria:
Inclusion Criteria:

1. Adults above age of 20
2. Undergoing Thoracic Aorta Surgery with Hypothermic Cardiac Arrest

Exclusion Criteria:

1. pregnancy or lactation
2. cerebrovascular thrombosis 3. past history of pulmonary embolism or thrombosis
3. past history of thoracic aortic surgery
4. malignancy 5. preoperative acute kidney injury
5. chronic renal replacement therapy
6. allergy or hypersensitivity to erythropoetin
7. history of erythropoetin treatment
8. death during or one day after surgery
9. no consent
10. reoperation within seven days of the first surgery
Effects of a Recreational Team Handball-based Programme on Health and Physical Fitness of Middle-aged and Older Men

The present study aims at analyzing the dose-response effects of a recreational team handball-based exercise programme on cardiovascular, metabolic, musculoskeletal and physical fitness markers of inactive middle-aged and older men, without previous experience with the sport. The researchers hypothesized a positive weekly training frequency effect on health and physical fitness outcomes.


Eligibility Criteria:
Inclusion Criteria:

* Male participants; inactive with 50 or more years of age (i.e., not complying with the physical activity guidelines for the last 6 months).

Exclusion Criteria:

* Any medical contraindication to perform moderate-to-vigorous physical activity; incapacity to run or grip a ball.
Frailty in Critical Care Unit's Patients

In the study ,investigator aim to evaluate the frailty syndrome in critically ill patients, in both young and old populations,to determine its imapct on outcome, and impact of ICU in fraility


Eligibility Criteria:
Inclusion Criteria:

* All ICU patients \>18 years

Exclusion Criteria:

* Age \<18 years
A Web Application for Improving Communication on Hemodialysis Rounds

To evaluate a web application tool that hemodialysis patients can use outside of dialysis time to log and prioritize their concerns for the nephrologists. Specifically, the investigators will compare the usability of a web application tool to a structured paper form. The investigators will also use data from semi-structured interviews to better understand the experience and acceptability of the web app among patient participants randomized to the web application and among participating nephrologists.

Primary outcome

-Usability (effectiveness, efficiency, satisfaction)

Secondary outcomes

-Quality of the patient-physician interaction (Communication Assessment Tool (CAT-14))

Usability is defined as Effectiveness (\>70%)

* Number of people submitting a concern/ number of people with opportunity to submit a concern
* Number of concerns entered/number of times concern was satisfactorily addressed

Efficiency

* Proportion of non-completed tasks (\<70%)
* The amount of time to complete one concern

Satisfaction

* Semistructured interviews
* Usability survey

Eligibility Criteria:
Inclusion Criteria:

* Chronic in-center hemodialysis patients in Edmonton, Alberta and Winnipeg, Manitoba
* Able to provide consent, understand and read English or have a family member that can do this for them

Exclusion Criteria:

* Planning to change modality within the next year
An Observational Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes Patients

An Observational Study to assess the Prevalence of Heart Failure in Type 2 Diabetes Patients in India.

This is a cross sectional, observational, multi-centre study to be conducted at 40 centres in India. The study targets to enrol 1000 patients with approx. 25 patients per site. The study would enrol Type 2 Diabetes Mellitus patients who provide written informed consent. No study medication will be prescribed or administered as a part of study procedure. Patients, who have been treated as per Investigators' routine clinical practice will be screened for enrolment in study. The study will be initiated after obtaining written approval of Independent Ethics Committee (IEC) /Institutional Review Board (IRB).

Eligibility Criteria:
Inclusion Criteria:

* Both men and women aged ≥ 18 years
* Diagnosed with type 2 diabetes (as per ADA Criteria)
* Duration of diabetes for 1 year or more
* Willing to provide the informed consent

Exclusion Criteria:

* Patients with evidence of coronary artery disease - CAD (based on the clinical expertise of the physician).
* Patients who were previously diagnosed with heart failure.
* Patients with evidence of valvular disease based on clinical judgement of the Principle Investigator (PI).
* Current treatment with digoxin.
* History of symptoms of peripheral artery disease, chronic obstructive pulmonary disease and arrhythmias.
* Patients diagnosed with stage III/IV CKD
* Diabetes other than type 2 diabetes mellitus.
The Placental Thickness and Pregnancy Outcomes in Placenta Previa Women

Placenta previa is the placenta overlying the cervical os. Placenta previa is about 1 in 200 pregnancies. The risk factors are the increasing rate of cesarean section and previous uterine surgery. Placenta previa is associated with many adverse complications; the most serious one is related to maternal hemorrhage. The diagnosis of placenta previa is done by trans-abdominal and trans-vaginal ultrasonography, which can document the placental edge's relationship to the internal os. Placenta accreta spectrum disorder is defined when trophoblastic invades the myometrium. The Placenta accreta spectrum can be categorized as: placenta accreta, placenta increta, and placenta percreta.

The clinical utility of placental thickness is an area of ongoing research in placenta previa. Prior studies have demonstrated an association between mid-trimester placental thickness and placenta accreta spectrum. Despite the presence of many studies in characterizing placental thickness, most studies have focused primarily on the placental accreta spectrum lacking information about other fetal and maternal complications. Symptomatic (bleeding) placenta previa is associated with increased maternal and neonatal morbidity and mortality. In addition; the mechanism that involves bleeding is unclear. It is usually related to uterine contractions, cervical effacement, and dilation leading to separation of the placenta from the underlying decidua.


Eligibility Criteria:
Inclusion Criteria:

1. Pregnant women from 32-34 weeks.
2. Pregnant women with singleton pregnancy.
3. Women with placenta previa.
4. Placenta previa with minimal vaginal bleeding or haven't any vaginal bleeding.
5. Women without any medical disorders.
6. Women should be living in a nearby area to make follow-up and early transportation is reasonably possible.

Exclusion Criteria:

1. Women with severe bleeding necessitate immediate delivery.
2. Women with confirmed fetal malformation.
3. If associated with abruptio placentae.
4. Women who will refuse to participate.
Targeting the Hippo Transducer TAZ in Breast Cancer With Statins

This pre-surgical, window-of-opportunity study is designed to investigate whether atorvastatin reduces the proliferation marker Ki-67 via modulation of the Hippo transducer TAZ.


Eligibility Criteria:
Inclusion:

* Signed written informed consent
* Female aged \>18 years and \<75 years at the time of the enrolment
* Histologically confirmed Breast Cancer (BC) independently on the intrinsic subtype
* Stage I-IIa BC patients candidate for elective surgery
* BC expressing Ki-67 ≥ 15% and TAZ \> 10% in diagnostic core biopsies
* Adequate baseline organ function
* Negative pregnancy test

Exclusion:

* Previous systemic therapy including chemotherapy, hormone therapy and targeted agents
* Administration of an investigational drug prior to enrolment
* History of another malignancy, except for a history of completely resected non-melanoma skin cancer or successfully treated cervical in situ carcinoma
* Eastern Cooperative Oncology Group (ECOG) performance status ≥2
* Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome and asymptomatic gallstones)
* Serious cardiac illness or medical conditions including but not confined to: history of documented congestive heart failure (CHF) or systolic dysfunction (LVEF \<50%); high-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block, supraventricular arrhythmias which are not adequately controlled); angina pectoris requiring antianginal medication; clinically significant valvular heart disease; evidence of transmural infarction on ECG; poorly controlled hypertension (e.g. systolic \>180mm Hg or diastolic \>100mm Hg)
* Have a concurrent disease or condition that may interfere with study participation, or any serious medical disorder that would interfere with the subject's safety (for example, active or uncontrolled infection or any psychiatric condition prohibiting understanding or rendering of informed consent)
* Current or recent therapy with statins for hypercholesterolemia or other lipid-lowering drugs
* Current or recent therapy with glucose-lowering drugs for diabetes
* Current or recent therapy with strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, itraconazole) given potential interactions with atorvastatin
* Current or recent therapy with gemfibrozil or other fibrates given potential interactions with atorvastatin.
* Patients who are pregnant or breastfeeding
The Knowledge Levels and Attitudes of the People Living in Nevşehir on Organ Donation and Transplantation

In this descriptive study, the purpose was to determine the knowledge levels and attitudes of the people in Nevsehir, Turkey on organ donation.

It has been determined that the people living in Nevsehir do not have sufficient knowledge on organ donation, they had various concerns on the issue, and they wanted to receive information from Organ Donation Units. It can be used the exemplification and internalization in educational curricula about increasing the organ donation.

Purpose

In this descriptive study,the purpose was to determine the knowledge levels and attitudes of the people in Nevsehir on organ donation.

Methods

The data of the study were collected with the questionnaire applied to 414 people residing in Nevşehir between February and May 2016. In evaluating the data, the numbers, percentage calculations, Chi-Square Test,t-test, and One-Way tests were used.

Eligibility Criteria:
Inclusion Criteria:

* Anyone aged between 20-65
* The people living in the city center of Nevşehir, Turkey

Exclusion Criteria:

* \<20 years old

  * 65 years old
* The people who do not live the city center of Nevşehir, Turkey
Individualized Medical Training and Calcipotriol and Betamethasone Dipropionate Gel in Plaque Psoriasis

The aim of the study will be to evaluate the impact of this individualized practical training on efficacy (evaluated by Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA) score performed by a physician blinded to the study groups) and adherence (calculated as days wherein gel was applied and as BSA/weight of gel applied rate) to a 4 week long treatment with dovobet gel. On the other hand, the investigators will evaluate in both groups as demographic (as sex, age, job,..) or disease (as severity, duration, impact of quality of life,..) characteristics influence the adherence to the treatment.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of psoriasis will be maid mainly on clinical findings. If doubts, a skin sample will be obtained and evaluated by histopathological examination.

Exclusion Criteria:

* Patients with palmoplantar, scalp, inverse, erythrodermic, guttate, pustular psoriasis will be excluded.
The CALERIE™ Legacy Study

The purpose of the CALERIE Legacy Study is to follow up on the health and wellness of participants from phase 2 of the Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE) trial, which was conducted from 2007 to 2011.

The CALERIE Legacy Study is an observational follow-up study of participants from phase 2 the CALERIE trial, the first randomized controlled trial of calorie restriction (CR) in humans without obesity. The overarching goal of the CALERIE Legacy Study is to examine whether two years of CR results in sustained improvements in the biological, phenotypic, and functional hallmarks of human aging 10 to 15 years after the structured intervention. Participants will complete clinical assessments, dietary recalls, and questionnaires, and laboratory evaluations will be performed on blood and urine samples. The study also includes an optional biospecimen banking component.

Eligibility Criteria:
Inclusion Criteria:

* Enrolled in the CALERIE trial and started their allocated group (CR intervention or ad libitum control condition)
* Willing and able to attend one of the clinical sites for an in-person visit and provide informed consent

Exclusion Criteria:

* Pregnant women
* Women less than 12 months postpartum
* Documented note from the CALERIE trial indicating that the subject should not be contacted or requested not to be contacted for future research
* Diagnosed active cancer or terminal illness
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).

Masked, randomized, single site, crossover study to compare 2 concentrations of QLS-101. Subjects will be randomized to one of 2 concentrations of QLS-101 for the first 14 days of daily dosing, and after a 14-day washout period they will be crossed over to the other concentration for another 14 days of daily dosing. Dose assignment is masked to patient and investigator.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with SWS.
* Elevated intraocular pressure (IOP)
* Willing to continue current dosing regimen of IOP-lowering medications
* Willing to refrain from contact lens use in the study eye.

Exclusion Criteria:

* IOP with variability of \> 4 mm Hg
* Expected to undergo IOP-lowering surgery
* Incisional or laser surgery of any type
* Ocular infection, inflammation, clinically significant blepharitis or conjunctivitis
* A history of herpes simplex keratitis in either eye.
* History of or active clinically significant ocular disease
* Use of topical ocular corticosteroids in the 6 weeks prior to Visit 1